-
This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
-
I think this article somewhat speaks for itself and why reporting is important and this is probably not the last story we will hear on this. If government had wanted to track this, a data base reporting system could have been set up with applicable laws a long time ago requiring payments to be...
-
We still need more labeling and the ability for consumers to identify products when recalls are sent out. Look a the Heparin recall that failed, and that was a drug. In a recent post I had some suggestions that can be read here, including disallowing “blind” shipments so it’s not a rat race t find...
-
This story about Walgreens illustrates a little bit of both. After the economy and Wall Street news of the last couple of weeks, we should know now about how programmers set algorithms to select, process and deliver data. Need a refresher, you can check here relative to Wall Street out coding...
-
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
-
Whistle blower case where Pharma Sales representative created an investigation and settlement. Whistle blowers can and do receive portions of settlements, and in this case there was $46 million. The uses marketed by Cephalon were not approved by the FDA. Doctors can prescribe...
-
By far one of the best tools out there and as a consumer there is a lot of information too on the free version, easy to find the various tiers for coverage and drug interactions. I also have the web based look up on the blog, so use it to look up any drug by just typing in the name. BD ...
-
What the top R and D managers from 4 big Pharma companies were talking about, yes they have a bit more of a cushion than Wall Street, but the failure rates and dollars invested don’t seem to be coming together too well either, from the Wall Street Health Blog. When you add it up, just these 4 were...
-
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
-
One more survey, do we really need to spend this money, I think we have a pretty good idea here that it is not many. My personal opinion here would be to spend the money and enable and educate folks on how this can be done, rather than to see how many can’t, it’s an obvious. If the money...